Header Logo

Connection

JOSEPH JANKOVIC to Middle Aged

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Middle Aged.
JOSEPH JANKOVIC
Connection Strength
4.216
Middle Aged
  1. Axial tics in Tourette syndrome and chronic tic disorders. J Neurol. 2024 Nov; 271(11):7232-7238.
    View in: PubMed
    Score: 0.058
  2. Treatment response to onabotulinumtoxinA in cervical dystonia patients with anterocollis and retrocollis. Toxicon. 2024 Sep; 248:108035.
    View in: PubMed
    Score: 0.057
  3. Functional Neurological Disorders Among Patients With Tremor. J Neuropsychiatry Clin Neurosci. 2025; 37(1):61-66.
    View in: PubMed
    Score: 0.057
  4. Medication refractory restless legs syndrome: Real-world experience. J Neurol Sci. 2024 Aug 15; 463:123121.
    View in: PubMed
    Score: 0.057
  5. Leg stereotypy syndrome: phenomenological and quantitative analysis. J Neurol. 2024 Aug; 271(8):5519-5524.
    View in: PubMed
    Score: 0.057
  6. Parkinson's disease after COVID-19. J Neurol Sci. 2021 03 15; 422:117331.
    View in: PubMed
    Score: 0.045
  7. Psychogenic (Functional) Movement Disorders. Continuum (Minneap Minn). 2019 Aug; 25(4):1121-1140.
    View in: PubMed
    Score: 0.041
  8. Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol. 2019 Mar/Apr; 42(2):37-41.
    View in: PubMed
    Score: 0.039
  9. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 10 01; 75(10):1206-1214.
    View in: PubMed
    Score: 0.038
  10. Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018 07 19; 10(7).
    View in: PubMed
    Score: 0.038
  11. Cervical dystonia and substance abuse. J Neurol. 2018 Apr; 265(4):970-975.
    View in: PubMed
    Score: 0.037
  12. Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study. Neurology. 2018 02 13; 90(7):e559-e564.
    View in: PubMed
    Score: 0.036
  13. Leg stereotypy syndrome: phenomenology and prevalence. J Neurol Neurosurg Psychiatry. 2018 07; 89(7):692-695.
    View in: PubMed
    Score: 0.036
  14. Functional (psychogenic) stereotypies. J Neurol. 2017 Jul; 264(7):1482-1487.
    View in: PubMed
    Score: 0.035
  15. Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017 May 15; 376:129-132.
    View in: PubMed
    Score: 0.034
  16. Examiner manoeuvres 'sensory tricks' in functional (psychogenic) movement disorders. J Neurol Neurosurg Psychiatry. 2017 05; 88(5):453-455.
    View in: PubMed
    Score: 0.034
  17. Distinguishing features of psychogenic (functional) versus organic hemifacial spasm. J Neurol. 2017 Feb; 264(2):359-363.
    View in: PubMed
    Score: 0.034
  18. Treatment of blepharospasm with apraclonidine. J Neurol Sci. 2017 Jan 15; 372:57-59.
    View in: PubMed
    Score: 0.034
  19. Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. Mov Disord. 2017 03; 32(3):433-440.
    View in: PubMed
    Score: 0.033
  20. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs. 2016 May; 76(7):779-87.
    View in: PubMed
    Score: 0.032
  21. Psychogenic Ophthalmologic Movement Disorders. J Neuropsychiatry Clin Neurosci. 2016; 28(3):195-8.
    View in: PubMed
    Score: 0.032
  22. Speech and voice disorders in patients with psychogenic movement disorders. J Neurol. 2015 Nov; 262(11):2420-4.
    View in: PubMed
    Score: 0.031
  23. Dopamine transporter imaging in essential tremor with and without parkinsonian features. J Neural Transm (Vienna). 2015 Nov; 122(11):1515-21.
    View in: PubMed
    Score: 0.031
  24. Dopa-responsive dystonia--clinical and genetic heterogeneity. Nat Rev Neurol. 2015 Jul; 11(7):414-24.
    View in: PubMed
    Score: 0.030
  25. Bolivian kindred with combined spinocerebellar ataxia types 2 and 10. Acta Neurol Scand. 2015 Aug; 132(2):139-42.
    View in: PubMed
    Score: 0.030
  26. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015 Feb 15; 349(1-2):84-93.
    View in: PubMed
    Score: 0.029
  27. Stiff-person syndrome: insights into a complex autoimmune disorder. J Neurol Neurosurg Psychiatry. 2015 Aug; 86(8):840-8.
    View in: PubMed
    Score: 0.029
  28. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism Relat Disord. 2014 Dec; 20(12):1345-51.
    View in: PubMed
    Score: 0.029
  29. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon. 2014 Nov; 90:344-8.
    View in: PubMed
    Score: 0.029
  30. The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry. 2014 May; 85(5):573-5.
    View in: PubMed
    Score: 0.027
  31. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014 Jan; 29(1):126-30.
    View in: PubMed
    Score: 0.027
  32. Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res. 2013 Aug; 24(2):298-306.
    View in: PubMed
    Score: 0.026
  33. Yips and other movement disorders in golfers. Mov Disord. 2013 May; 28(5):576-81.
    View in: PubMed
    Score: 0.026
  34. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013 Feb; 28(2):210-5.
    View in: PubMed
    Score: 0.026
  35. Respiratory disorders associated with dystonia. Mov Disord. 2012 Dec; 27(14):1816-9.
    View in: PubMed
    Score: 0.026
  36. Amplitude fluctuations in essential tremor. Parkinsonism Relat Disord. 2012 Aug; 18(7):859-63.
    View in: PubMed
    Score: 0.025
  37. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord. 2012 Jun; 18(5):488-93.
    View in: PubMed
    Score: 0.024
  38. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011 Nov 04; 11:140.
    View in: PubMed
    Score: 0.024
  39. Convergence spasm in conversion disorders: prevalence in psychogenic and other movement disorders compared with controls. J Neurol Neurosurg Psychiatry. 2012 Feb; 83(2):202-4.
    View in: PubMed
    Score: 0.023
  40. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011 Sep; 17(8):625-8.
    View in: PubMed
    Score: 0.023
  41. Exploring the correlates of intermediate CAG repeats in Huntington disease. Postgrad Med. 2011 Sep; 123(5):116-21.
    View in: PubMed
    Score: 0.023
  42. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul; 26(8):1521-8.
    View in: PubMed
    Score: 0.023
  43. Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders. J Neuropsychiatry Clin Neurosci. 2011; 23(2):141-8.
    View in: PubMed
    Score: 0.022
  44. Asian over-representation among patients with hemifacial spasm compared to patients with cranial-cervical dystonia. J Neurol Sci. 2010 Nov 15; 298(1-2):61-3.
    View in: PubMed
    Score: 0.022
  45. Tourette's syndrome in adults. Mov Disord. 2010 Oct 15; 25(13):2171-5.
    View in: PubMed
    Score: 0.022
  46. Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor. Mov Disord. 2010 Sep 15; 25(12):1938-43.
    View in: PubMed
    Score: 0.022
  47. Examination of the MASH1 gene in patients with Parkinson's disease. Biochem Biophys Res Commun. 2010 Feb 19; 392(4):548-50.
    View in: PubMed
    Score: 0.021
  48. Examination of the MSX1 gene in patients with Parkinson's disease. Acta Neurol Scand. 2009 Dec; 120(6):442-4.
    View in: PubMed
    Score: 0.021
  49. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009 Dec; 16 Suppl 2:14-8.
    View in: PubMed
    Score: 0.021
  50. Genetic analysis of the NEUROG2 gene in patients with Parkinson's disease. Neurosci Lett. 2010 Jan 14; 468(3):195-7.
    View in: PubMed
    Score: 0.021
  51. Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci. 2009 Dec 15; 287(1-2):159-71.
    View in: PubMed
    Score: 0.020
  52. Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010 Mar; 81(3):315-9.
    View in: PubMed
    Score: 0.020
  53. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 Jan; 81(1):70-3.
    View in: PubMed
    Score: 0.020
  54. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009 Oct 15; 285(1-2):195-7.
    View in: PubMed
    Score: 0.020
  55. Motor overflow and mirror dystonia. Parkinsonism Relat Disord. 2009 Dec; 15(10):758-61.
    View in: PubMed
    Score: 0.020
  56. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009 Sep 15; 284(1-2):177-8.
    View in: PubMed
    Score: 0.020
  57. Epidemiology and management of essential tremor in children. Paediatr Drugs. 2009; 11(5):293-307.
    View in: PubMed
    Score: 0.019
  58. Applause sign in Parkinsonian disorders and Huntington's disease. Mov Disord. 2008 Dec 15; 23(16):2307-11.
    View in: PubMed
    Score: 0.019
  59. Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol. 2008 Aug; 14(4):253-4.
    View in: PubMed
    Score: 0.019
  60. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008 May-Jun; 31(3):127-33.
    View in: PubMed
    Score: 0.019
  61. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist. 2008 Mar; 14(2):89-99.
    View in: PubMed
    Score: 0.018
  62. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008 Mar; 48(3):379-84.
    View in: PubMed
    Score: 0.018
  63. Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. Neurosci Lett. 2008 Jan 03; 430(1):18-22.
    View in: PubMed
    Score: 0.018
  64. Tardive gait. Clin Neurol Neurosurg. 2008 Feb; 110(2):198-201.
    View in: PubMed
    Score: 0.018
  65. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008 Jul; 79(7):789-95.
    View in: PubMed
    Score: 0.018
  66. Hemiparkinsonism-hemiatrophy syndrome. Neurology. 2007 Oct 16; 69(16):1585-94.
    View in: PubMed
    Score: 0.018
  67. Focal hand dystonia, mirror dystonia and motor overflow. J Neurol Sci. 2008 Mar 15; 266(1-2):31-3.
    View in: PubMed
    Score: 0.018
  68. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):256-65.
    View in: PubMed
    Score: 0.018
  69. The other Babinski sign in hemifacial spasm. Neurology. 2007 Jul 24; 69(4):402-4.
    View in: PubMed
    Score: 0.018
  70. Alexia without agraphia in Creutzfeldt-Jakob disease. J Neurol Sci. 2007 Dec 15; 263(1-2):208-10.
    View in: PubMed
    Score: 0.018
  71. Distinguishing psychogenic and essential tremor. J Neurol Sci. 2007 Dec 15; 263(1-2):94-9.
    View in: PubMed
    Score: 0.018
  72. The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. J Neurol Sci. 2007 Sep 15; 260(1-2):199-203.
    View in: PubMed
    Score: 0.017
  73. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007 May; 64(5):676-82.
    View in: PubMed
    Score: 0.017
  74. Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. Neurosci Lett. 2007 May 29; 419(2):104-7.
    View in: PubMed
    Score: 0.017
  75. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007 Apr; 106(4):621-5.
    View in: PubMed
    Score: 0.017
  76. Genetics of essential tremor. Brain. 2007 Jun; 130(Pt 6):1456-64.
    View in: PubMed
    Score: 0.017
  77. A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol. 2007 Mar; 64(3):421-4.
    View in: PubMed
    Score: 0.017
  78. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15; 22(2):193-7.
    View in: PubMed
    Score: 0.017
  79. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007 Jan; 22(1):10-3.
    View in: PubMed
    Score: 0.017
  80. Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord. 2007 Jan; 22(1):127-30.
    View in: PubMed
    Score: 0.017
  81. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
    View in: PubMed
    Score: 0.017
  82. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007 Jan 31; 252(2):113-20.
    View in: PubMed
    Score: 0.017
  83. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006 Dec 21; 251(1-2):102-6.
    View in: PubMed
    Score: 0.017
  84. Runner's dystonia. J Neurol Sci. 2006 Dec 21; 251(1-2):73-6.
    View in: PubMed
    Score: 0.017
  85. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006 Nov; 21(11):1856-63.
    View in: PubMed
    Score: 0.017
  86. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neurosci Lett. 2006 Oct 23; 407(2):97-100.
    View in: PubMed
    Score: 0.017
  87. Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord. 2006 Aug; 21(8):1252-4.
    View in: PubMed
    Score: 0.016
  88. Psychogenic tremor: long-term outcome. CNS Spectr. 2006 Jul; 11(7):501-8.
    View in: PubMed
    Score: 0.016
  89. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006 Jul 11; 103(28):10753-8.
    View in: PubMed
    Score: 0.016
  90. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Sep; 12(6):382-7.
    View in: PubMed
    Score: 0.016
  91. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2006 May; 21(5):692-5.
    View in: PubMed
    Score: 0.016
  92. Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. Mov Disord. 2006 May; 21(5):728-9.
    View in: PubMed
    Score: 0.016
  93. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006 Apr; 104(4):506-12.
    View in: PubMed
    Score: 0.016
  94. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci Lett. 2006 Jun 19; 401(1-2):16-9.
    View in: PubMed
    Score: 0.016
  95. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol. 2006 Feb; 63(2):273-7.
    View in: PubMed
    Score: 0.016
  96. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005 Dec; 76(12):1636-9.
    View in: PubMed
    Score: 0.016
  97. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005 Sep 13; 65(5):765-7.
    View in: PubMed
    Score: 0.015
  98. Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease. Neurology. 2005 Aug 23; 65(4):651-2.
    View in: PubMed
    Score: 0.015
  99. Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005 Aug 09; 65(3):355-9.
    View in: PubMed
    Score: 0.015
  100. G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients. Acta Neurol Scand. 2005 Jun; 111(6):351-2.
    View in: PubMed
    Score: 0.015
  101. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol. 2005 Jun; 57(6):933-4.
    View in: PubMed
    Score: 0.015
  102. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005 May; 20(5):592-7.
    View in: PubMed
    Score: 0.015
  103. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005; 20 Suppl 11:S11-6.
    View in: PubMed
    Score: 0.015
  104. Factor analysis and clustering of motor and psychiatric dimensions in idiopathic blepharospasm. Parkinsonism Relat Disord. 2025 Feb; 131:107241.
    View in: PubMed
    Score: 0.015
  105. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004 Nov-Dec; 27(6):274-7.
    View in: PubMed
    Score: 0.015
  106. Premutation alleles associated with Parkinson disease and essential tremor. JAMA. 2004 Oct 13; 292(14):1685-6.
    View in: PubMed
    Score: 0.015
  107. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology. 2004 Sep 28; 63(6):1096-8.
    View in: PubMed
    Score: 0.014
  108. Minocycline in Huntington's disease: a pilot study. Mov Disord. 2004 Jun; 19(6):692-5.
    View in: PubMed
    Score: 0.014
  109. Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. Neurology. 2024 02 27; 102(4):e208091.
    View in: PubMed
    Score: 0.014
  110. Basal ganglia neuronal discharge in primary and secondary dystonia. Adv Neurol. 2004; 94:29-36.
    View in: PubMed
    Score: 0.014
  111. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord. 2004 Jan; 19(1):36-42.
    View in: PubMed
    Score: 0.014
  112. Migraine headache in patients with Tourette syndrome. Arch Neurol. 2003 Nov; 60(11):1595-8.
    View in: PubMed
    Score: 0.014
  113. Hearing impairment in essential tremor. Neurology. 2003 Oct 28; 61(8):1093-7.
    View in: PubMed
    Score: 0.014
  114. Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery. 2003 Jun; 52(6):1358-70; discussion 1370-3.
    View in: PubMed
    Score: 0.013
  115. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003 Apr 08; 60(7):1186-8.
    View in: PubMed
    Score: 0.013
  116. Soleus H-reflex measures in patients with focal and generalized dystonia. Clin Neurophysiol. 2003 Feb; 114(2):288-94.
    View in: PubMed
    Score: 0.013
  117. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002 Nov-Dec; 25(6):300-2.
    View in: PubMed
    Score: 0.013
  118. Secondary paroxysmal dyskinesias. Mov Disord. 2002 Jul; 17(4):726-34.
    View in: PubMed
    Score: 0.012
  119. H-reflex recovery curves differentiate essential tremor, Parkinson's disease, and the combination of essential tremor and Parkinson's disease. J Clin Neurophysiol. 2002 Jun; 19(3):245-51.
    View in: PubMed
    Score: 0.012
  120. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002 Mar; 59(3):421-4.
    View in: PubMed
    Score: 0.012
  121. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002 Mar; 8(4):271-6.
    View in: PubMed
    Score: 0.012
  122. Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis. JAMA Neurol. 2022 02 01; 79(2):185-193.
    View in: PubMed
    Score: 0.012
  123. Dystonia in spinocerebellar ataxia type 6. Mov Disord. 2002 Jan; 17(1):150-3.
    View in: PubMed
    Score: 0.012
  124. Methods of H-reflex evaluation in the early stages of Parkinson's disease. J Clin Neurophysiol. 2002 Jan; 19(1):67-72.
    View in: PubMed
    Score: 0.012
  125. Secondary causes of paroxysmal dyskinesia. Adv Neurol. 2002; 89:401-20.
    View in: PubMed
    Score: 0.012
  126. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001 Oct 23; 57(8):1392-6.
    View in: PubMed
    Score: 0.012
  127. Functional decline in Parkinson disease. Arch Neurol. 2001 Oct; 58(10):1611-5.
    View in: PubMed
    Score: 0.012
  128. Diagnostic criteria for blepharospasm: A multicenter international study. Parkinsonism Relat Disord. 2021 10; 91:109-114.
    View in: PubMed
    Score: 0.012
  129. Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application. Neurosurgery. 2001 Mar; 48(3):535-41; discussion 541-3.
    View in: PubMed
    Score: 0.011
  130. Dystonia in corticobasal degeneration. Mov Disord. 2001 Mar; 16(2):252-7.
    View in: PubMed
    Score: 0.011
  131. Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. Parkinsonism Relat Disord. 2021 03; 84:105-111.
    View in: PubMed
    Score: 0.011
  132. Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. Mov Disord. 2001 Jan; 16(1):114-8.
    View in: PubMed
    Score: 0.011
  133. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm (Vienna). 2001; 108(1):63-70.
    View in: PubMed
    Score: 0.011
  134. Effects of pallidotomy on gait and balance. Adv Neurol. 2001; 87:271-81.
    View in: PubMed
    Score: 0.011
  135. Psychogenic hemifacial spasm. J Neuropsychiatry Clin Neurosci. 2001; 13(3):380-4.
    View in: PubMed
    Score: 0.011
  136. Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort. Neurology. 2021 01 26; 96(4):e563-e574.
    View in: PubMed
    Score: 0.011
  137. Botulinum toxin in the treatment of tics. Arch Neurol. 2000 Aug; 57(8):1190-3.
    View in: PubMed
    Score: 0.011
  138. Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism Relat Disord. 2020 09; 78:56-60.
    View in: PubMed
    Score: 0.011
  139. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000 Jul; 15(4):678-82.
    View in: PubMed
    Score: 0.011
  140. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000 Mar; 57(3):369-72.
    View in: PubMed
    Score: 0.011
  141. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000 Feb; 68(2):186-90.
    View in: PubMed
    Score: 0.010
  142. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000 Feb; 131(2):211-6.
    View in: PubMed
    Score: 0.010
  143. Postural Directionality and Head Tremor in Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2020; 10.
    View in: PubMed
    Score: 0.010
  144. Essential tremor: clinical characteristics. Neurology. 2000; 54(11 Suppl 4):S21-5.
    View in: PubMed
    Score: 0.010
  145. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. J Parkinsons Dis. 2020; 10(2):543-558.
    View in: PubMed
    Score: 0.010
  146. Functional gait disorders, clinical phenomenology, and classification. Neurol Sci. 2020 Apr; 41(4):911-915.
    View in: PubMed
    Score: 0.010
  147. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999 Dec 10; 53(9):2102-7.
    View in: PubMed
    Score: 0.010
  148. Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord. 2019 09; 66:166-170.
    View in: PubMed
    Score: 0.010
  149. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999 Aug; 156(8):1279-81.
    View in: PubMed
    Score: 0.010
  150. Levodopa-induced dyskinesias treated by pallidotomy. J Neurol Sci. 1999 Aug 01; 167(1):62-7.
    View in: PubMed
    Score: 0.010
  151. Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. J Neurol Sci. 2019 Oct 15; 405:116413.
    View in: PubMed
    Score: 0.010
  152. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov Disord. 1999 Jul; 14(4):664-8.
    View in: PubMed
    Score: 0.010
  153. Bruxism and cranial-cervical dystonia: is there a relationship? Cranio. 1999 Jul; 17(3):196-201.
    View in: PubMed
    Score: 0.010
  154. Exercise performance in those having Parkinson's disease and healthy normals. Med Sci Sports Exerc. 1999 Jun; 31(6):761-6.
    View in: PubMed
    Score: 0.010
  155. Head tremor at disease onset: an ataxic phenotype of cervical dystonia. J Neurol. 2019 Aug; 266(8):1844-1851.
    View in: PubMed
    Score: 0.010
  156. Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and a-synuclein mechanisms. Mov Disord. 2019 06; 34(6):866-875.
    View in: PubMed
    Score: 0.010
  157. Bilateral hemifacial spasm: a report of five cases and a literature review. Mov Disord. 1999 Mar; 14(2):345-9.
    View in: PubMed
    Score: 0.010
  158. Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999 Jan; 14(1):57-62.
    View in: PubMed
    Score: 0.010
  159. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999 Jan; 56(1):98-102.
    View in: PubMed
    Score: 0.010
  160. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol. 1999 Jan-Feb; 22(1):1-4.
    View in: PubMed
    Score: 0.010
  161. Attitudes toward neurosurgical procedures for Parkinson's disease and obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1999; 11(2):259-67.
    View in: PubMed
    Score: 0.010
  162. Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998 Dec; 21(12):1740-7.
    View in: PubMed
    Score: 0.010
  163. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry. 1998 Nov; 65(5):722-8.
    View in: PubMed
    Score: 0.010
  164. Predictors of alcohol responsiveness in dystonia. Neurology. 2018 11 20; 91(21):e2020-e2026.
    View in: PubMed
    Score: 0.010
  165. Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. Parkinsonism Relat Disord. 2019 03; 60:126-132.
    View in: PubMed
    Score: 0.010
  166. Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson's disease. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8567-E8576.
    View in: PubMed
    Score: 0.009
  167. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998 Jun; 50(6):1624-9.
    View in: PubMed
    Score: 0.009
  168. Post-traumatic movement disorders: effect of the legal system on outcome. J Forensic Sci. 1998 Mar; 43(2):334-9.
    View in: PubMed
    Score: 0.009
  169. Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Mov Disord. 2018 03; 33(3):468-472.
    View in: PubMed
    Score: 0.009
  170. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain. 2017 12 01; 140(12):3191-3203.
    View in: PubMed
    Score: 0.009
  171. The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. Immunol Invest. 2018 Jan; 47(1):18-39.
    View in: PubMed
    Score: 0.009
  172. Tics secondary to craniocerebral trauma. Mov Disord. 1997 Sep; 12(5):776-82.
    View in: PubMed
    Score: 0.009
  173. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurol. 2017 08 01; 74(8):977-982.
    View in: PubMed
    Score: 0.009
  174. ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism Relat Disord. 2017 Aug; 41:37-43.
    View in: PubMed
    Score: 0.009
  175. Psychiatric associations of adult-onset focal dystonia phenotypes. J Neurol Neurosurg Psychiatry. 2017 07; 88(7):595-602.
    View in: PubMed
    Score: 0.009
  176. Thalamic DBS with a constant-current device in essential tremor: A?controlled clinical trial. Parkinsonism Relat Disord. 2017 Jul; 40:18-26.
    View in: PubMed
    Score: 0.009
  177. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb; 48(2):358-62.
    View in: PubMed
    Score: 0.009
  178. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 01; 74(2):216-224.
    View in: PubMed
    Score: 0.009
  179. Improvement of parkinsonian signs after vascular lesions of the basal ganglia circuitry. Mov Disord. 1997 Jan; 12(1):124-6.
    View in: PubMed
    Score: 0.008
  180. Thalamic surgery for movement disorders. Adv Neurol. 1997; 74:221-33.
    View in: PubMed
    Score: 0.008
  181. [Medial posteroventral pallidotomy for the treatment of Parkinson's disease]. Zentralbl Neurochir. 1997; 58(4):153-62.
    View in: PubMed
    Score: 0.008
  182. Understanding falls in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017 02; 35:75-81.
    View in: PubMed
    Score: 0.008
  183. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017 Jan 10; 88(2):152-159.
    View in: PubMed
    Score: 0.008
  184. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996 Dec; 47(6):1435-41.
    View in: PubMed
    Score: 0.008
  185. Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016 11 15; 300:36-46.
    View in: PubMed
    Score: 0.008
  186. Propofol-induced dyskinesias in Parkinson's disease. Anesth Analg. 1996 Aug; 83(2):420-22.
    View in: PubMed
    Score: 0.008
  187. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 05; 316(1):40-50.
    View in: PubMed
    Score: 0.008
  188. Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet. 2016 07; 48(7):733-9.
    View in: PubMed
    Score: 0.008
  189. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996 May; 11(3):250-6.
    View in: PubMed
    Score: 0.008
  190. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016 Apr; 31(4):563-9.
    View in: PubMed
    Score: 0.008
  191. Delayed-onset progressive movement disorders after static brain lesions. Neurology. 1996 Jan; 46(1):68-74.
    View in: PubMed
    Score: 0.008
  192. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10.
    View in: PubMed
    Score: 0.008
  193. Whole-Exome Sequencing in Familial Parkinson Disease. JAMA Neurol. 2016 Jan; 73(1):68-75.
    View in: PubMed
    Score: 0.008
  194. Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Immunobiology. 2016 Apr; 221(4):568-76.
    View in: PubMed
    Score: 0.008
  195. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995 Oct; 38(4):571-9.
    View in: PubMed
    Score: 0.008
  196. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995 Oct; 37(4):680-6; discussion 686-7.
    View in: PubMed
    Score: 0.008
  197. Response and immunoresistance to botulinum toxin injections. Neurology. 1995 Sep; 45(9):1743-6.
    View in: PubMed
    Score: 0.008
  198. Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Mov Disord. 2015 Dec; 30(14):1885-92.
    View in: PubMed
    Score: 0.008
  199. Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J Med Genet. 1995 Jul; 32(7):516-8.
    View in: PubMed
    Score: 0.008
  200. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.008
  201. A Pilot Study of a Cognitive-Behavioral Treatment for Anxiety and Depression in Patients With Parkinson Disease. J Geriatr Psychiatry Neurol. 2015 Sep; 28(3):210-7.
    View in: PubMed
    Score: 0.008
  202. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015 Jul; 14(7):710-9.
    View in: PubMed
    Score: 0.008
  203. Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects. Neurology. 1995 Apr; 45(4):645-8.
    View in: PubMed
    Score: 0.007
  204. Peripherally induced tremor and parkinsonism. Arch Neurol. 1995 Mar; 52(3):263-70.
    View in: PubMed
    Score: 0.007
  205. Post-traumatic movement disorders: central and peripheral mechanisms. Neurology. 1994 Nov; 44(11):2006-14.
    View in: PubMed
    Score: 0.007
  206. Neurohistopathological findings at the electrode-tissue interface in long-term deep brain stimulation: systematic literature review, case report, and assessment of stimulation threshold safety. Neuromodulation. 2014 Jul; 17(5):405-18; discussion 418.
    View in: PubMed
    Score: 0.007
  207. CAG repeat size and clinical presentation in Huntington's disease. Neurology. 1994 Jun; 44(6):1137-43.
    View in: PubMed
    Score: 0.007
  208. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 2014 Aug; 29(9):1171-80.
    View in: PubMed
    Score: 0.007
  209. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry. 2014 Aug; 85(8):882-4.
    View in: PubMed
    Score: 0.007
  210. Botulinum toxin in the treatment of dystonic tics. Mov Disord. 1994 May; 9(3):347-9.
    View in: PubMed
    Score: 0.007
  211. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014 Jul; 261(7):1309-19.
    View in: PubMed
    Score: 0.007
  212. The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry. 2014 May; 85(5):567-72.
    View in: PubMed
    Score: 0.007
  213. What is it? Case 1, 1993: parkinsonism, dysautonomia, and ophthalmoparesis. Mov Disord. 1993 Oct; 8(4):525-32.
    View in: PubMed
    Score: 0.007
  214. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014 Feb; 20(2):142-8.
    View in: PubMed
    Score: 0.007
  215. Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg Am. 1993 Sep; 18(5):883-7.
    View in: PubMed
    Score: 0.007
  216. Hereditary motor-sensory neuropathy and movement disorders. Muscle Nerve. 1993 Sep; 16(9):904-10.
    View in: PubMed
    Score: 0.007
  217. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993 Jul; 95(1):38-48.
    View in: PubMed
    Score: 0.007
  218. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology. 1993 May; 43(5):937-41.
    View in: PubMed
    Score: 0.007
  219. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology. 2013 May 28; 80(22):2022-7.
    View in: PubMed
    Score: 0.007
  220. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993 Apr; 43(4):834-6.
    View in: PubMed
    Score: 0.007
  221. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(?)) injections in blepharospasm. J Neural Transm (Vienna). 2013 Sep; 120(9):1345-53.
    View in: PubMed
    Score: 0.006
  222. Psychogenic myoclonus. Neurology. 1993 Feb; 43(2):349-52.
    View in: PubMed
    Score: 0.006
  223. Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct; 27(12):1567-9.
    View in: PubMed
    Score: 0.006
  224. Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome. Sleep Med. 2012 Oct; 13(9):1202-4.
    View in: PubMed
    Score: 0.006
  225. The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992 Sep; 55(9):806-10.
    View in: PubMed
    Score: 0.006
  226. Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012; 90(5):300-6.
    View in: PubMed
    Score: 0.006
  227. Alternating verbal fluency performance following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease. Eur J Neurol. 2012 Dec; 19(12):1525-31.
    View in: PubMed
    Score: 0.006
  228. Acoustic reflex abnormalities in cranial-cervical dystonia. Neurology. 1992 Mar; 42(3 Pt 1):594-7.
    View in: PubMed
    Score: 0.006
  229. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol. 2012 Feb; 11(2):140-9.
    View in: PubMed
    Score: 0.006
  230. Head injury, a-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012 Jan; 71(1):40-8.
    View in: PubMed
    Score: 0.006
  231. Tardive tremor. Mov Disord. 1992; 7(1):53-7.
    View in: PubMed
    Score: 0.006
  232. Persistent dystonia possibly induced by flecainide. Mov Disord. 1992; 7(1):62-3.
    View in: PubMed
    Score: 0.006
  233. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord. 2012 Feb; 27(2):284-8.
    View in: PubMed
    Score: 0.006
  234. Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991 Dec; 48(12):1253-6.
    View in: PubMed
    Score: 0.006
  235. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
    View in: PubMed
    Score: 0.006
  236. Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. J Neurol Sci. 2012 Feb 15; 313(1-2):35-41.
    View in: PubMed
    Score: 0.006
  237. The coexistence of tics and dystonia. Arch Neurol. 1991 Aug; 48(8):862-5.
    View in: PubMed
    Score: 0.006
  238. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN?, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15; 308(1-2):103-9.
    View in: PubMed
    Score: 0.006
  239. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
    View in: PubMed
    Score: 0.006
  240. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991 Jul; 41(7):1088-91.
    View in: PubMed
    Score: 0.006
  241. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol. 2012 Jan; 19(1):121-7.
    View in: PubMed
    Score: 0.006
  242. Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord. 2011 Aug; 17(7):537-42.
    View in: PubMed
    Score: 0.006
  243. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011 May; 10(5):415-23.
    View in: PubMed
    Score: 0.006
  244. Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease. Mov Disord. 2011 Aug 01; 26(9):1729-32.
    View in: PubMed
    Score: 0.006
  245. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol. 2011 Apr; 178(4):1509-16.
    View in: PubMed
    Score: 0.006
  246. Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord. 2011 Jun; 17(5):321-7.
    View in: PubMed
    Score: 0.006
  247. Essential tremor: clinical correlates in 350 patients. Neurology. 1991 Feb; 41(2 ( Pt 1)):234-8.
    View in: PubMed
    Score: 0.006
  248. Stiff-person syndrome: an autoimmune disease. Mov Disord. 1991; 6(1):12-20.
    View in: PubMed
    Score: 0.006
  249. Orthostatic tremor: an association with essential tremor. Mov Disord. 1991; 6(1):60-4.
    View in: PubMed
    Score: 0.006
  250. CSF A?(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord. 2010 Nov 15; 25(15):2682-5.
    View in: PubMed
    Score: 0.006
  251. Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov Disord. 2010 Oct 30; 25(14):2470-2.
    View in: PubMed
    Score: 0.006
  252. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
    View in: PubMed
    Score: 0.006
  253. LINGO1 rs9652490 variant in Parkinson disease patients. Neurosci Lett. 2011 Jan 07; 487(2):174-6.
    View in: PubMed
    Score: 0.006
  254. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990 Oct; 40(10):1529-34.
    View in: PubMed
    Score: 0.005
  255. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011 Jan; 26(1):147-52.
    View in: PubMed
    Score: 0.005
  256. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990 Aug; 53(8):633-9.
    View in: PubMed
    Score: 0.005
  257. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010 Jul; 68(1):18-27.
    View in: PubMed
    Score: 0.005
  258. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010 Aug 09; 480(1):78-82.
    View in: PubMed
    Score: 0.005
  259. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010 May; 31(5):561-8.
    View in: PubMed
    Score: 0.005
  260. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990 May; 83(5):525-32.
    View in: PubMed
    Score: 0.005
  261. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics. 2010 Oct; 11(4):401-8.
    View in: PubMed
    Score: 0.005
  262. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23.
    View in: PubMed
    Score: 0.005
  263. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010 Mar; 133(Pt 3):713-26.
    View in: PubMed
    Score: 0.005
  264. Botulinum toxin injections for cervical dystonia. Neurology. 1990 Feb; 40(2):277-80.
    View in: PubMed
    Score: 0.005
  265. Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. Adv Neurol. 1990; 53:293-304.
    View in: PubMed
    Score: 0.005
  266. Tardive oculogyric crises. Neurology. 1989 Nov; 39(11):1434-7.
    View in: PubMed
    Score: 0.005
  267. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med. 1989 Nov; 149(11):2486-92.
    View in: PubMed
    Score: 0.005
  268. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24; 361(13):1268-78.
    View in: PubMed
    Score: 0.005
  269. Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease. Neurology. 1989 Sep; 39(9):1227-34.
    View in: PubMed
    Score: 0.005
  270. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009 Sep; 66(9):1106-13.
    View in: PubMed
    Score: 0.005
  271. Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol. 1989 Aug; 46(8):862-7.
    View in: PubMed
    Score: 0.005
  272. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1306-11.
    View in: PubMed
    Score: 0.005
  273. Dystonia in musicians. Semin Neurol. 1989 Jun; 9(2):131-5.
    View in: PubMed
    Score: 0.005
  274. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics. 2009 Oct; 10(4):347-53.
    View in: PubMed
    Score: 0.005
  275. GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients. Neurosci Lett. 2009 May 01; 454(3):209-11.
    View in: PubMed
    Score: 0.005
  276. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord. 1989; 4(4):303-9.
    View in: PubMed
    Score: 0.005
  277. Dystonia and tremor induced by peripheral trauma: predisposing factors. J Neurol Neurosurg Psychiatry. 1988 Dec; 51(12):1512-9.
    View in: PubMed
    Score: 0.005
  278. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008 Nov 15; 23(15):2194-201.
    View in: PubMed
    Score: 0.005
  279. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.005
  280. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008 Sep 23; 71(13):1040; author reply 1040-1.
    View in: PubMed
    Score: 0.005
  281. Parkinson's disease: recent advances in therapy. South Med J. 1988 Aug; 81(8):1021-7.
    View in: PubMed
    Score: 0.005
  282. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60.
    View in: PubMed
    Score: 0.005
  283. Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease. Surg Neurol. 2009 May; 71(5):551-8.
    View in: PubMed
    Score: 0.005
  284. Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology. 1988 Apr; 38(4):522-7.
    View in: PubMed
    Score: 0.005
  285. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008 Apr; 129(4):526-9.
    View in: PubMed
    Score: 0.005
  286. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988 Mar; 38(3):391-4.
    View in: PubMed
    Score: 0.005
  287. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res. 2008 Feb; 7(2):720-30.
    View in: PubMed
    Score: 0.005
  288. Depressed mood and memory impairment before and after unilateral posteroventral pallidotomy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2008; 20(3):357-63.
    View in: PubMed
    Score: 0.005
  289. Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol. 1988; 49:103-16.
    View in: PubMed
    Score: 0.005
  290. Orofacial and other self-mutilations. Adv Neurol. 1988; 49:365-81.
    View in: PubMed
    Score: 0.005
  291. Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. Adv Neurol. 1988; 49:117-23.
    View in: PubMed
    Score: 0.005
  292. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987 Dec; 10(6):511-21.
    View in: PubMed
    Score: 0.005
  293. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007 Dec; 22(16):2371-7.
    View in: PubMed
    Score: 0.005
  294. Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis. Acta Neurochir (Wien). 2007; 149(9):857-66; discussion 866.
    View in: PubMed
    Score: 0.004
  295. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69(4):342-7.
    View in: PubMed
    Score: 0.004
  296. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord. 2008; 14(1):77-80.
    View in: PubMed
    Score: 0.004
  297. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord. 2007 Mar 15; 22(4):546-9.
    View in: PubMed
    Score: 0.004
  298. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007 Jan 23; 68(4):272-6.
    View in: PubMed
    Score: 0.004
  299. Tardive myoclonus. Mov Disord. 1987; 2(4):307-11.
    View in: PubMed
    Score: 0.004
  300. Blepharospasm and autoimmune diseases. Mov Disord. 1987; 2(3):159-63.
    View in: PubMed
    Score: 0.004
  301. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007 Jan; 22(1):55-61.
    View in: PubMed
    Score: 0.004
  302. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain. 2006 Sep; 129(Pt 9):2318-31.
    View in: PubMed
    Score: 0.004
  303. HS1-BP3 gene variant is common in familial essential tremor. Mov Disord. 2006 Mar; 21(3):306-9.
    View in: PubMed
    Score: 0.004
  304. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006 Mar 14; 66(5):672-7.
    View in: PubMed
    Score: 0.004
  305. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.004
  306. The phenomenology of tics. Mov Disord. 1986; 1(1):17-26.
    View in: PubMed
    Score: 0.004
  307. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91.
    View in: PubMed
    Score: 0.004
  308. Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder. Mov Disord. 2004 Oct; 19(10):1237-8.
    View in: PubMed
    Score: 0.004
  309. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004 Jul; 61(7):1044-53.
    View in: PubMed
    Score: 0.004
  310. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004 Jun 08; 62(11):2005-9.
    View in: PubMed
    Score: 0.004
  311. Effects of visual and auditory cues on gait in individuals with Parkinson's disease. J Neurol Sci. 2004 Apr 15; 219(1-2):63-9.
    View in: PubMed
    Score: 0.004
  312. Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci. 2004 Jan 15; 217(1):89-99.
    View in: PubMed
    Score: 0.003
  313. Phenotypic features of Huntington's disease-like 2. Mov Disord. 2003 Dec; 18(12):1527-30.
    View in: PubMed
    Score: 0.003
  314. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003 Dec 15; 12(24):3259-67.
    View in: PubMed
    Score: 0.003
  315. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
    View in: PubMed
    Score: 0.003
  316. Haplotype analysis of the ETM2 locus in familial essential tremor. Neurogenetics. 2003 Aug; 4(4):185-9.
    View in: PubMed
    Score: 0.003
  317. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology. 2003 Apr 08; 60(7):1189-91.
    View in: PubMed
    Score: 0.003
  318. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 2003 Jan; 33(1):85-9.
    View in: PubMed
    Score: 0.003
  319. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002 Mar 26; 58(6):881-4.
    View in: PubMed
    Score: 0.003
  320. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002 Apr; 70(4):985-93.
    View in: PubMed
    Score: 0.003
  321. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001 Nov 14; 286(18):2239-44.
    View in: PubMed
    Score: 0.003
  322. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA. 2001 Nov 14; 286(18):2245-50.
    View in: PubMed
    Score: 0.003
  323. Thalamic deep brain stimulation: effects on the nontarget limbs. Mov Disord. 2001 Nov; 16(6):1137-42.
    View in: PubMed
    Score: 0.003
  324. Alcohol dehydrogenase polymorphism and Parkinson's disease. Neurosci Lett. 2001 Jun 01; 305(1):70-2.
    View in: PubMed
    Score: 0.003
  325. Comparison of thalamotomy and pallidotomy for the treatment of dystonia. Neurosurgery. 2001 Apr; 48(4):818-24; discussion 824-6.
    View in: PubMed
    Score: 0.003
  326. Thalamic deep brain stimulation: comparison between unilateral and bilateral placement. Arch Neurol. 2001 Feb; 58(2):218-22.
    View in: PubMed
    Score: 0.003
  327. Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease. Neurology. 2000 Oct 24; 55(8):1218-22.
    View in: PubMed
    Score: 0.003
  328. Postural control in Parkinson's disease after unilateral posteroventral pallidotomy. Brain. 2000 Oct; 123 ( Pt 10):2141-9.
    View in: PubMed
    Score: 0.003
  329. Neuropsychological outcome after unilateral pallidotomy for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000 Sep; 69(3):326-36.
    View in: PubMed
    Score: 0.003
  330. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology. 2000 Mar 14; 54(5):1195-8.
    View in: PubMed
    Score: 0.003
  331. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999 Sep; 2(3):191-2.
    View in: PubMed
    Score: 0.003
  332. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999 May; 66(5):612-6.
    View in: PubMed
    Score: 0.002
  333. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol. 1999 Feb; 56(2):194-200.
    View in: PubMed
    Score: 0.002
  334. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol. 1999 Jan; 56(1):90-4.
    View in: PubMed
    Score: 0.002
  335. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch Neurol. 1998 Dec; 55(12):1521-3.
    View in: PubMed
    Score: 0.002
  336. Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology. 1998 Oct; 51(4):1063-9.
    View in: PubMed
    Score: 0.002
  337. Posteroventral medial pallidotomy for treatment of Parkinson's disease: preoperative magnetic resonance imaging features and clinical outcome. J Neurosurg. 1998 Aug; 89(2):194-9.
    View in: PubMed
    Score: 0.002
  338. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998 Jul; 55(7):969-78.
    View in: PubMed
    Score: 0.002
  339. Pallidotomy for generalized dystonia. Mov Disord. 1998 Jul; 13(4):693-8.
    View in: PubMed
    Score: 0.002
  340. Assessment of motor function after stereotactic pallidotomy. Neurology. 1998 Jan; 50(1):266-70.
    View in: PubMed
    Score: 0.002
  341. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 1998 Jan; 13(1):150-4.
    View in: PubMed
    Score: 0.002
  342. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1997 Nov; 63(5):642-8.
    View in: PubMed
    Score: 0.002
  343. Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg. 1997 Sep; 87(3):358-67.
    View in: PubMed
    Score: 0.002
  344. Molecular detection of new mutations, resolution of ambiguous results and complex genetic counseling issues in Huntington disease. Am J Med Genet. 1996 Dec 18; 66(3):281-6.
    View in: PubMed
    Score: 0.002
  345. Outcome after stereotactic thalamotomy for dystonia and hemiballismus. Neurosurgery. 1995 Mar; 36(3):501-7; discussion 507-8.
    View in: PubMed
    Score: 0.002
  346. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995; 7(4):471-5.
    View in: PubMed
    Score: 0.002
  347. Blepharospasm-oromandibular dystonia associated with a left cerebellopontine angle meningioma. J Emerg Med. 1990 Sep-Oct; 8(5):571-4.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.